# Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

> **NCT00086515** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 701 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** Sitagliptin (MK0431)
- **DRUG:** Placebo/Glipizide 5 mg
- **DRUG:** Metformin
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00086515
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-30
- **Primary completion:** 2005-07-20
- **Final completion:** 2007-02-02
- **Target enrollment:** 701 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086515, "Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00086515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*